QBioMed commercialises cancer pain drug less than a year after licensing deal

Q BioMed Inc (OTCQB:QBIO) reached a major milestone – bringing its radiopharmaceutical product Strontium-89 Chloride to market.

Production of the treatment for  metastatic breast and prostate cancer bone pain has occurred in less than a year since the firm signed the licensing agreement.

Around 70% of all patients with advanced breast and prostate cancer will develop bone metastases, which is extremely painful.

Bone metastases most prevalent in cancers of the breast, prostate, and lung.

AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be used with, or reduce the need for opiate drugs, as well as in combination with other cancer therapeutics.

A relief from pain..

Relief from the pain can come as little as one to two weeks and can last several months, the firm said.

Clinical studies have shown that for many people, alternating weekly chemohormonal therapies with Sr89 demonstrated a prolonged and progression-free survival.

A major milestone…

Chief executive Denis Corin said: “This is a major milestone in our short history.

“We are very excited to bring this product to market less than one year after finalizing the licensing agreement. There is an acute demand for an affordable and effective alternative to opiate based drugs in this patient population.

“We know this proven drug is effective and well tolerated with limited side-effects.

“We look forward to making it available as widely as possible and as quickly as possible. We believe there is significant opportunity to build this franchise and expand the revenue opportunity associated with it.”

QBioMed is focused on licensing and acquiring biomedical assets across healthcare and supporting their development to provide products to patients in need.

Shares raced up today 12.53% at $4.04 each.

Story by ProactiveInvestors